On June 5, 2024, Eli Lilly and Company announced that Ms. Anat Ashkenazi resigned as executive vice president of the Company to pursue another career opportunity outside of the pharmaceutical industry. Ms. Ashkenazi will remain at the Company through the end of July 2024 to facilitate the transition of her responsibilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
950.5 USD | +0.24% |
|
+3.54% | +63.05% |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
07-12 | Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.05% | 856B | |
+39.39% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+5.19% | 234B | |
+16.27% | 226B | |
+14.63% | 177B | |
+1.08% | 165B | |
+2.63% | 126B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company Announces Resignation of Anat Ashkenazi Resigned as Executive Vice President